AB-207 is under clinical development by Angiocrine Bioscience and currently in Phase I for Anal Fissure. According to GlobalData, Phase I drugs for Anal Fissure does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AB-207 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-207 overview
E-CEL UVEC is under development for the treatment of anal fistula, anal fissure and arthroscopic rotator cuff repair. It is administered as infusion and through intramuscular route. The drug candidate is developed based on E-CEL technology which utilizes VeraVec endothelial cells genetically modified by insertion of the adenovirus E4ORF1 gene and growth factors to stem cells. It was under development for genetic diseases.
It was also under development for the treatment of 2nd GI tract repair indication and soft tissue reconstruction.
Angiocrine Bioscience overview
Angiocrine Bioscience (Angiocrine) is a clinical-stage biopharmaceutical company that develops Advanced Reparative Medicines consisting of engineered human endothelial cells (E-CEL cells). Its pipeline products include AB-205, AB-207, AB-255 and AB-225. Its AB-205 is an experimental engineered cell therapy consisting of allogeneic E4ORF1+ human umbilical vein endothelial cells (E-CEL cells). The company utilizes its proprietary E-CEL Platform to create multiple versions of E-CEL cells to repair damaged tissues and organs and to treat serious medical conditions. Angiocrine is headquartered in San Diego, California, the US.
For a complete picture of AB-207’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
